Learn more about the role of Tuberculosis in cancer and how a simple vaccine supports the immune system to fight it.

Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study,” published in the ...

Two doses of a simple tuberculosis vaccination after surgery helps the immune system fight cancer cells and could greatly improve patient outcomes for the most common type of bladder cancer, according ...

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who ...

CG Oncology (CGON) announced that 83 out of 110 patients achieved a complete response at any time in a Phase 3 study of cretostimogene ...

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle ...